Modeling Principle

The DBA/1 mouse collagen-induced arthritis model (CIA) is a recognized classic and standardized autoimmune arthritis animal model in translational research on rheumatoid arthritis (RA), widely applied in RA pathogenesis research, pharmacodynamic evaluation of anti-inflammatory/immunomodulatory drugs, preclinical validation of biologics (anti-TNF-α, anti-IL-6R, etc.) and bone erosion protection strategies. Modeling principle: genetically susceptible DBA/1 mice are immunized with heterologous type Ⅱ collagen (bovine or chicken origin) emulsion to break immune tolerance against self type Ⅱ collagen. Type Ⅱ collagen-specific T cells are activated and B cells produce high-titer anti-type Ⅱ collagen antibodies (anti-CII IgG). Antibodies bind to type Ⅱ collagen on articular cartilage surface forming immune complexes, activating complement cascade and recruiting neutrophils and macrophages to infiltrate the synovium, inducing symmetrical polyarthritis. Meanwhile, Th1/Th17 cell-mediated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17) are massively released, driving synovial hyperplasia, pannus formation, cartilage degradation and bone erosion, ultimately presenting joint swelling, dysfunction, cartilage destruction and bone erosion, completely recapitulating the classic pathological cascade of human RA synovitis-cartilage damage-bone destruction. The DBA/1 strain carries a specific MHC class Ⅱ (H-2q) haplotype with strong immune response to type Ⅱ collagen, serving as a highly susceptible strain for CIA model with high incidence, typical arthritis phenotype and excellent reproducibility. This model combines both autoantibody-mediated and T cell-mediated dual immune mechanisms, highly homologous to the pathogenesis of human RA, serving as an in-vivo gold-standard model for evaluating novel RA drugs, biologics, targeted small molecules, natural anti-inflammatory products and bone-protective therapeutic strategies.

Model Validation Criteria

Quantitative Criteria for Clinical and Serological Validation

1. Incidence: CIA model group achieves arthritis incidence ≥80%, average arthritis index of affected mice ≥6 (total score 16) with symmetrical polyarthritis; 2. Joint swelling: hind limb ankle joint swelling of model group significantly increased compared with normal control (P<0.05), swelling persists ≥7 days; 3. Serology: serum anti-CII IgG antibody titer of model group significantly elevated (predominantly IgG2a subtype, indicating Th1/Th17-biased response); serum TNF-α, IL-1β, IL-6 and IL-17 levels significantly higher than normal control; 4. Positive drug validation: arthritis score and incidence of MTX or anti-TNF-α positive control group significantly reduced compared with model group (P<0.05), confirming sensitive and effective pharmacodynamic evaluation system, and the CIA model is judged successfully established.

Imaging and Histopathological Gold-Standard Indexes

1. X-ray/Micro-CT imaging: model group hind limb joints show joint space narrowing, periarticular soft tissue swelling, bone erosion/destruction foci and osteoporosis signs; semi-quantitative score (joint destruction score 0–4) significantly elevated compared with normal control; 2. HE staining: synovial hyperplasia and thickening, pannus formation, massive infiltration of inflammatory cells (neutrophils, lymphocytes, macrophages), joint cavity exudation, cartilage surface erosion and bone destruction; 3. Safranin O-fast green staining: loss of cartilage matrix proteoglycan, cartilage thinning and fissure formation; 4. TRAP staining: significantly increased osteoclast number at synovium-bone junction, indicating activated bone resorption; 5. Immunohistochemistry: anti-CII deposition in synovial tissue, increased TNF-α/IL-17 positive cells. These pathological changes are highly consistent with human RA synovitis-pannus-cartilage destruction-bone erosion features, jointly validating the pathological establishment of the model.

Academic Evidence for Model Validity

Core validation evidence for DBA/1 mouse CIA model: ① genetically susceptible strain produces strong autoimmune response to type Ⅱ collagen with high incidence and typical arthritis phenotype; ② combines both anti-CII antibody-mediated and T cell-mediated dual immune mechanisms, highly homologous to human RA pathogenesis; ③ multi-dimensional indexes including arthritis score, joint swelling, anti-CII antibody, inflammatory factors, imaging and pathology are reproducible and cross-validated; ④ positive drug control system validated effective, confirming model sensitivity to drug intervention; ⑤ model evaluates prophylactic/therapeutic administration strategies and bone-protective effects. Combined verification of above indexes confirms model reliability and reproducibility, serving as the recognized in-vivo gold-standard model for RA drug development and mechanism research.

Model Advantages

The DBA/1 mouse CIA model is a recognized classic autoimmune arthritis model in RA translational research, with pathogenesis highly homologous to human RA (autoantibody + T cell dual mechanism). The DBA/1 highly susceptible strain achieves high incidence (≥80%), typical arthritis phenotype, excellent reproducibility and low intra-group variation. Multi-dimensional indicators including incidence, arthritis score, joint swelling, anti-CII antibody, inflammatory factors, imaging and pathology can be quantitatively evaluated with complete evidence chain. Both prophylactic and therapeutic administration protocols are supported, compatible with pharmacodynamic evaluation of chemical drugs, biologics (anti-TNF-α, anti-IL-6R), targeted small molecules, natural anti-inflammatory products and bone-protective strategies. Pathological features (synovitis, pannus, cartilage destruction, bone erosion) are highly consistent with human RA with high translational value. Results are readily accepted by rheumatology and pharmacology SCI journals, suitable for NSFC projects, postgraduate dissertations and research proposals.

Research Applications

The DBA/1 mouse CIA model is mainly applied to dissect the complete pathological mechanism of rheumatoid arthritis including breakdown of autoimmune tolerance, T/B cell responses, pro-inflammatory cytokine network, synovial hyperplasia, pannus formation, cartilage degradation and bone erosion; to perform in-vivo pharmacodynamic evaluation of anti-inflammatory/immunomodulatory drugs, biologics (anti-TNF-α, anti-IL-6R), JAK inhibitors, targeted small molecules, natural anti-inflammatory products and bone-protective treatment strategies; to optimize prophylactic/therapeutic administration protocols and investigate synergistic effects of combination therapy; to excavate novel therapeutic targets (RANKL, IL-17, JAK/STAT, etc.) and regulatory networks of RA. It extensively serves basic rheumatology research, anti-RA new drug development, NSFC projects, postgraduate dissertations and SCI manuscript methodology construction, acting as an indispensable standardized in-vivo gold-standard model in RA translational medicine.

DBA/1 mouse collagen-induced arthritis model, type Ⅱ collagen-induced arthritis CIA, rheumatoid arthritis animal model, autoimmune arthritis, arthritis index score, anti-type Ⅱ collagen antibody, synovial inflammation and bone erosion, RA drug efficacy evaluation